Purchase this article with an account.
Lucia Rivera Sanchez, Alejandra Ruiz Franco, Juan Abel Ramirez Estudillo, Victor Manuel Bautista de Lucio; Clinical response to intravitreal Rapamycin in a retinal neovascularization model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1217.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the clinical and fluorangiography response to intravitreal Rapamycin in a retinal neovascularization model induced with vascular endothelial growth factor (VEGF165).
We performed a retinal neovascularization model in three New Zealand rabbits by intravitreal application of VEGF (8μg/0.1ml). Once neovascularization was developed, two rabbits where treated with 333μg/0.1ml of intravitreal Rapamycin. Rabbit without treatment was used as control. Clinical and fluorangiographyc follow was done at seventh and fourthteen day.
At third day after VEGF was applied, neovascularization of anterior segment was evidenced in all rabbits. At first week, retinal neovascularization was clinical and fluorangiography demonstrable. One rabbit developed a fibrovascular proliferation and small pre-retinal hemorrhage. Indirect ophthalmoscopy and fluorangiography showed partial regression of the neovascularization seven days after Rapamycin treatment, this regression continued until day fourthteen, where no clinical evidence of neovascularization was observed, and neither hiperfluorescence phenomenon. Likewise, there was partial regression of fibrovascular proliferation without retinal detachment.
Intravitreal Rapamycin at 333μg/0.1ml concentration caused clinical and fluorangiographyc regression of retinal neovascularization in an experimental model induced by VEGF165.
This PDF is available to Subscribers Only